SCHEMBL259075

SCHEMBL259075

CCCCCCCCCCCCCCCCc1ncccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KCNH2 Q12809 2/20 0.43
DHFR P00374 1/20 0.38
HSD11B1 P28845 1/20 0.38
KDM4E B2RXH2 3/20 0.36
LMNA P02545 3/20 0.36
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
HTT P42858 1/20 0.36
NPC1 O15118 1/20 0.36
HSP90AA1 P07900 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TBXAS1 P24557 1/20 0.36
PPARA Q07869 1/20 0.36
TRPV1 Q8NER1 3/20 0.36
LIPG Q9Y5X9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11119746 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL4607711 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL29908366 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL29791423 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL28673468 1.00 TDP1 (0.47) TDP1L3MBTL1KCNH2DHFRHSD11B1
Water SCHEMBL3623340 0.98 TDP1 (0.46) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL15639197 0.98 TDP1 (0.49) TDP1L3MBTL1KCNH2DHFRHSD11B1
SCHEMBL9544351 0.93 L3MBTL1 (0.42) TDP1L3MBTL1KDM4ELMNANPC1
SCHEMBL10246570 0.85 PDE4A (0.39) L3MBTL1KDM4E
SCHEMBL11629358 0.84 HSD11B1 (0.44) TDP1L3MBTL1KCNH2HSD11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12618090-B2 Method for increasing the extraction rate of chondroitin sulfate prepared from tilapia skull GUANGDONG OCEAN UNIVERSITY (CN) 2026-05-05 US claimed
US-12324850-B2 Compositions and methods for cleaning, decontamination and treating subjects exposed to chemical irritants REFLEX RED STORM, LLC. (US) 2025-06-10 US claimed
CN-120078026-A Use of alkylpyridinium salts for controlling plant parasitic nematodes 兰州大学 2025-06-03 CN claimed
CN-119031839-A Compositions comprising an antimicrobial agent and an alkyl ketal ester compound 西姆莱斯股份公司 2024-11-26 CN claimed
US-20240247293-A1 METHOD FOR INCREASING THE EXTRACTION RATE OF CHONDROITIN SULFATE PREPARED FROM TILAPIA SKULL GUANGDONG OCEAN UNIVERSITY (CN) 2024-07-25 US claimed
CN-118005521-A Synthesis method of benzocaine 陕西科技大学 2024-05-10 CN claimed
CN-118005501-A Method for preparing mandelic acid 陕西科技大学 2024-05-10 CN claimed
CN-117603679-A Preparation method of ratio type fluorescent probe and application of ratio type fluorescent probe in detection of cetyl pyridine bromide 河南师范大学 2024-02-27 CN claimed
CN-117531489-A Polymer-loaded modified black talc composite adsorbent and preparation method and application thereof 浙江工业大学 2024-02-09 CN claimed
WO-2024022108-A1 ORAL CARE CLEANING SHEET, AND PREPARATION METHOD AND USE METHOD THEREFOR 广州洁生日化有限公司 2024-02-01 WO claimed
WO-2002027827-A1 TUNGSTEN-CONTAINING FUEL CELL CATALYST AND METHOD OF MAKING SAME OSRAM SYLVANIA, INC. (US) 2002-04-04 WO claimed
EP-0711546-B1 OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCINE AND ITS APPLICATIONS ALCON CUSI S A (ES) 2001-01-03 EP claimed
EP-0592348-B1 Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use CUSI LAB (ES) 1998-01-07 EP claimed
US-5679665-A Pharmaceutical formulation comprised of polymyxintrimethoprim and an anti-inflammatory drug for ophthalmic and otic topical use LABORATORIOS CUSI, S.A. (ES) 1997-10-21 US claimed
EP-0711546-A1 OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS LABORATORIOS CUSI, S.A. (ES) 1996-05-15 EP claimed
EP-0661055-A1 Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof LABORATORIOS CUSI, S.A. (ES) 1995-07-05 EP claimed
EP-0592348-A1 Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use LABORATORIOS CUSI, S.A. (ES) 1994-04-13 EP claimed
EP-0012926-B1 SOLUTIONS OF X-RAY CONTRAST AGENTS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1984-03-07 EP claimed
WO-1980001244-A1 X-RAY CONTRAST MEDIA SOLUTIONS BYKGULDEN LOMBERG CHEM FAB (DE) 1980-06-26 WO claimed
US-3960724-A BROWN COAL NOVEX TALALMANYFEJLESZTO ES ERTEKESITO KULKERESKEDELMI RT. (HU) 1976-06-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12618090-B2 Method for increasing the extraction rate of chondroitin sulfate prepared from tilapia skull MMP2, MMP13, MMP14 TDP1 1056/4885L3MBTL1 4613/4885KCNH2 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.